Articles / Innovation
RNOH research project wins award at global oncology conference
High-dose capsaicin patches (8% concentration) are a topical treatment for chronic neuropathic pain. Unlike over-the-counter creams, these patches deliver a powerful dose of capsaicin, an extract from chili peppers, directly to the affected area. The treatment is locally acting, meaning it targets pain at the site of application without affecting the rest of the body.
Capsaicin binds to TRPV1 receptors on pain-sensing nerves in the skin. Initially, this causes a warming or burning sensation, but it quickly leads to desensitisation of the nerves. The patch depletes substance P, a chemical involved in pain transmission, resulting in a temporary reduction in nerve sensitivity.
This targeted approach:
Clinical studies show that a single application of a high-dose capsaicin patch can provide relief for up to 12 weeks, with enhanced benefits from repeated treatments. In long-term trials:
The capsaicin patch is well-tolerated and acts locally, avoiding systemic side effects like drowsiness or dizziness. Common temporary reactions include:
Healthcare professionals apply a numbing agent beforehand and offer cooling gels afterwards to ease discomfort. The treatment is safe for older adults and does not cause permanent nerve damage.
High-dose capsaicin patches offer a safe, effective, and non-systemic option for managing neuropathic pain. Administered by specialists like Mr Ashley Simpson, this therapy can be part of a comprehensive pain management plan, helping patients regain comfort and function.
Some patients feel a burning sensation during application, but this is temporary and managed with numbing agents and cooling gels.
Relief can last up to 12 weeks from a single application, with increasing benefit from repeated treatments.
Yes. Clinical studies show it is well-tolerated across age groups, with minimal systemic side effects.
Yes. RNOH Private Care is the private care unit of the Royal National Orthopaedic NHS Trust, with all surplus funds being reinvested into NHS services.